Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid Early Stage Poor Prognosis CLL Trial
ISRCTN84606869Phase 2Completed
- Sponsor
- The Christie
- Start
- Apr 2010
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by The Christie. Primary endpoint: Complete remission with minimal residual disease clearance. Started Apr 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN84606869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN84606869.